Health equity
As the first wave of the COVID pandemic washed across the world, it left devastation in its wake – devastation that was persistently most acute among disadvantaged people and in marginalized communities. COVID made obvious what many already knew: Inequity—whether because of race, culture, skin color, income or caste—can be lethal.
This Innovations In is editorially independent, produced with financial support from a third party. About this content.
Nature is pleased to acknowledge financial support from Takeda Pharmaceuticals in producing this Innovations In. The sponsor retains sole responsibility for the following message.
Takeda Pharmaceutical Company Limited is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions.
In November 2020, Takeda launched the Center for Health Equity and Patient Affairs to strengthen our commitment to addressing health inequities and reinforce our mission to create better health for people and a brighter future for the world. The Center works with Takeda’s business units, functions, and external partners to identify opportunities to provide early patient access to Takeda medicines, accelerate the time to diagnosis for children with rare diseases, engage patients throughout the drug development process, and share scientific and technical knowledge with partners across multiple sectors to help strengthen health research and delivery systems to address barriers at various stages of the patient journey. Our aim is that this innovative model will enable Takeda to create a more inclusive ecosystem and strengthen trust with communities and patients around the world.
